Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress.

Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress.
复制标题

DOI:
10.3389/fphar.2021.641210
复制
发表时间:
2021
影响因子:
5.6
通讯作者:
Montopoli M
Montopoli M
中科院分区:
医学2区
文献类型:
--
作者:
Cocetta V;Governa P;Borgonetti V;Tinazzi M;Peron G;Catanzaro D;Berretta M;Biagi M;Manetti F;Dall'Acqua S;Montopoli M

文献摘要

参考文献

被引文献

相似文献

在过去的50年中,肠道疾病(IBD)的相关性和发病率一直在增加,目前的治疗以严重的副作用为特征,因此开发联合收割机在人类IBD管理中的有效性和安全性相结合的新策略至关重要。草药产品在旨在发现IBD治疗新方法的研究中受到高度重视,其中包括大麻。几个世纪以来,传统上一直用作镇痛和抗炎药物,也用于不同的胃肠道疾病。本研究旨在探讨不同的C. Sativa分离的化合物在肠上皮细胞的体外模型中的表达。在Caco-2肠细胞单层上测试治疗调节肠功能障碍标志物的能力。通过评估ROS产生、TEER和细胞旁通透性测量以及紧密连接评估获得的我们的结果显示大麻二酚是对抗肠道炎症状况的最有前途的化合物。大麻二酚能够在炎症和氧化应激条件下抑制ROS产生并恢复上皮通透性,表明其可能用作IBD管理中的佐剂。
The relevance and incidence of intestinal bowel diseases (IBD) have been increasing over the last 50 years and the current therapies are characterized by severe side effects, making essential the development of new strategies that combine efficacy and safety in the management of human IBD. Herbal products are highly considered in research aimed at discovering new approaches for IBD therapy and, among others, Cannabis sativa L. has been traditionally used for centuries as an analgesic and anti-inflammatory remedy also in different gastrointestinal disorders. This study aims to investigate the effects of different C. sativa isolated compounds in an in vitro model of intestinal epithelium. The ability of treatments to modulate markers of intestinal dysfunctions was tested on Caco-2 intestinal cell monolayers. Our results, obtained by evaluation of ROS production, TEER and paracellular permeability measurements and tight junctions evaluation show Cannabidiol as the most promising compound against intestinal inflammatory condition. Cannabidiol is able to inhibit ROS production and restore epithelial permeability during inflammatory and oxidative stress conditions, suggesting its possible application as adjuvant in IBD management.
DOI: 10.1016/j.bbi.2019.04.006
发表时间: 2020-03-01
影响因子: 15.1
作者:
Guida, Francesca;Boccella, Serena;Maione, Sabatino
通讯作者: Maione, Sabatino
DOI: 10.1155/2015/179616
发表时间: 2015
影响因子: 4.6
作者:
Algieri F;Rodriguez-Nogales A;Rodriguez-Cabezas ME;Risco S;Ocete MA;Galvez J
通讯作者: Galvez J
DOI: 10.1016/j.jchromb.2009.11.004
发表时间: 2009-12-15
影响因子: 3
作者:
De Backer, Benjamin;Debrus, Benjamin;Charlier, Corinne
通讯作者: Charlier, Corinne
DOI: 10.1136/gut.2005.090472
发表时间: 2006-10-01
期刊: GUT
影响因子: 24.5
作者:
Di Marzo, V.;Izzo, A. A.
通讯作者: Izzo, A. A.
DOI: 10.1111/j.1572-0241.1999.01444.x
发表时间: 1999-10-01
影响因子: 9.8
作者:
D'Incà, R;Di Leo, V;Sturniolo, GC
通讯作者: Sturniolo, GC